Shinnihonseiyaku Co., Ltd. Logo

Shinnihonseiyaku Co., Ltd.

Develops, manufactures, and sells cosmetics, pharmaceuticals, and health foods.

4931 | T

Overview

Corporate Details

ISIN(s):
JP3381200009
LEI:
Country:
Japan
Address:
福岡市中央区大手門一丁目4番7号

Description

Shinnihonseiyaku Co., Ltd. develops, manufactures, and sells cosmetics, pharmaceuticals, and health foods. The company's core business revolves around mail-order sales of its products. Its flagship skincare brand, Perfect One, is known for its focus on simplicity and collagen-based formulations. In the pharmaceutical sector, the company develops products to address various diseases and symptoms. Its health food division offers products made from carefully selected ingredients, emphasizing quality and ease of consumption to support customers' well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-02-08 07:00
四半期報告書-第36期第1四半期(2023/10/01-2023/12/31)
Japanese ZIP 153.6 KB
2023-12-20 07:01
臨時報告書
Japanese ZIP 32.3 KB
2023-12-20 07:01
内部統制報告書-第35期(2022/10/01-2023/09/30)
Japanese ZIP 23.8 KB
2023-12-20 07:00
有価証券報告書-第35期(2022/10/01-2023/09/30)
Japanese ZIP 1.4 MB
2023-12-20 07:00
確認書
Japanese ZIP 8.8 KB
2023-08-10 08:00
確認書
Japanese ZIP 8.8 KB
2023-08-10 08:00
四半期報告書-第35期第3四半期(2023/04/01-2023/06/30)
Japanese ZIP 158.6 KB
2023-05-11 08:00
確認書
Japanese ZIP 8.8 KB
2023-05-11 08:00
四半期報告書-第35期第2四半期(2023/01/01-2023/03/31)
Japanese ZIP 195.5 KB
2023-02-09 07:00
四半期報告書-第35期第1四半期(2022/10/01-2022/12/31)
Japanese ZIP 159.2 KB
2023-02-09 07:00
確認書
Japanese ZIP 8.8 KB
2022-12-21 07:00
有価証券報告書-第34期(令和3年10月1日-令和4年9月30日)
Japanese ZIP 1.1 MB
2022-12-21 07:00
内部統制報告書-第34期(令和3年10月1日-令和4年9月30日)
Japanese ZIP 23.7 KB
2022-12-21 07:00
確認書
Japanese ZIP 8.8 KB
2022-08-10 08:00
確認書
Japanese ZIP 8.8 KB

Automate Your Workflow. Get a real-time feed of all Shinnihonseiyaku Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shinnihonseiyaku Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shinnihonseiyaku Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.